Related Experiment Video
Updated: Feb 16, 2026
07:15
In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
Published on: October 20, 2013
9.8K
Targeting IL-17 in psoriatic arthritis
Elizabeth A Wang1, Erika Suzuki2, Emanual Maverakis1
1Department of Dermatology, UC Davis School of Medicine, CA, USA.
European Journal of Rheumatology
|January 9, 2018
Summary
Psoriatic arthritis (PsA) is a chronic condition linked to psoriasis. New biologics targeting the interleukin-17 (IL-17) pathway show promise for patients unresponsive to anti-TNF therapies.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a chronic, progressive inflammatory condition associated with psoriasis, significantly impacting quality of life.
- Current treatments like TNF antagonists are ineffective for a substantial number of PsA patients.
- The interleukin-17 (IL-17) signaling pathway is increasingly recognized for its role in PsA and psoriasis pathogenesis.
Purpose of the Study:
- To review the role of the IL-17/IL-17 receptor (IL-17R) pathway in the pathogenesis of PsA.
- To examine the clinical efficacy of IL-17 and IL-17R targeted biologics in treating PsA.
Main Methods:
- Literature review of studies investigating IL-17 and IL-17R in PsA.
- Analysis of clinical trial data for IL-17 and IL-17R targeted therapies.
Main Results:
- IL-17 and IL-17R play a significant role in the inflammatory processes underlying PsA.
- Biologics targeting the IL-17 pathway have demonstrated notable efficacy in managing PsA symptoms.
- These targeted therapies offer a promising alternative for patients refractory to anti-TNF treatments.
Conclusions:
- The IL-17 pathway is a critical target for PsA treatment development.
- IL-17 and IL-17R targeted biologics represent a significant advancement in managing PsA, particularly for non-responders to existing therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:26Targets for Drug Action: Overview
10.6K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K
01:22Target Cell Response to Hormones
5.8K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
01:29Pharmacogenomics: Identification of New Drug Targets
9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
01:24Modified-Release Drug Delivery Systems: Site-Targeted
18
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
18
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
17
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
17